Mabylon AG has received three grants totaling more than CHF 1.3 million from Innosuisse Swiss Innovation Agency, Target ALS, and the ALS Association. The funding is dedicated to advancing the development of human-derived TDP-43 intrabodies for amyotrophic lateral sclerosis (ALS) and the further development of Mabylon's MY012 program for the treatment of inflammatory bowel disease (IBD) with superior safety and efficacy.